A 1-year course of methotrexate (MTX) in clinically suspected arthralgia may prevent the development of rheumatoid arthritis (RA) in at-risk individuals who test negative for anti-citrullinated protein antibody (ACPA), according to 4-year results from the TREAT EARLIER study. While 2-year data did not show a preventive effect, researchers risk-stratified patients in this most recent data. The previous study also grouped...
Tag: <span>Methotrexate</span>
Post
Use of methotrexate is associated with an increased risk of skin cancer
UNIVERSITY OF GOTHENBURG The immunosuppressive drug methotrexate (MTX) can be linked to an elevated risk of three types of skin cancer, a new study by University of Gothenburg researchers shows. Patients receiving the drug include those with moderate to severe psoriasis; but in this particular patient group, a risk increase was only observed for basal...
Post
Antibody but not T-cell response after first dose of Pfizer COVID-19 vaccine is weakened in patients receiving methotrexate
EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES *Note: this paper is being presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) and is being published in The Lancet Rheumatology. Please credit both the congress and the journal in your stories* A new study presented at this year’s European Congress of Clinical Microbiology...
Post
Tuberculosis screening needed for methotrexate users in at-risk locales
AMERICAN COLLEGE OF RHEUMATOLOGY ATLANTA — New research presented at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that tuberculosis (TB) screening and ongoing clinical care is needed for people on methotrexate who live in areas where the highly infectious illness is common. Methotrexate users who also take corticosteroids or other immunosuppressant therapies are at...
Post
Methotrexate improves function in people with knee OA after 3 months
AMERICAN COLLEGE OF RHEUMATOLOGY ATLANTA — A new study presented at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that after three months of treatment with oral methotrexate, adults with primary knee osteoarthritis (OA) with inflammation had significant improvements in physical function and inflammation, a sign that this inexpensive, generic pill may be...